Literature DB >> 17041885

Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.

Najmunnisa Nasreen1, Kamal A Mohammed, Veena B Antony.   

Abstract

BACKGROUND: The over-expression of the ephrin-A1 ligand receptor EphA2 is associated with the growth and metastatic potential of tumors. Although EphA2 is expressed in a variety of tumors, its expression and function in malignant mesothelioma (MM) remain unknown. The authors hypothesized that expression of the receptor EphA2 in MM cells (MMCs) plays a key role in the growth and haptotactic migration of MM. They also hypothesized that silencing EphA2 expression by using small-interfering RNA (siRNA) inhibits the proliferation and haptotaxis of MMCs and induces apoptosis in MMCs.
METHODS: The expression of EphA2 in MMCs and in normal pleural mesothelial cells (PMCs) was studied by using real-time quantitative polymerase chain reaction analysis and Western blot analysis. The growth of MMCs was determined with the WST-1 cell-proliferation assay. The haptotactic migration of MMCs and PMCs was determined with a Boyden chamber assay. Expression of caspases was determined with calorimetric assays.
RESULTS: The results demonstrated that silencing the receptor EphA2 by siRNA significantly reduced the proliferation and haptotactic migration of MMCs compared with controls. Over-expression of EphA2 with plasmid pcDNA/EphA2 enhanced the proliferation and haptotaxis of MMCs significantly. Knocking down EphA2 expression initiated caspase-9-mediated apoptosis in MMCs.
CONCLUSIONS: The current results suggested that constitutive expression of EphA2 may contribute to the aggressive behavior and cellular survival of MMCs. EphA2 may be an effective therapeutic target in patients with mesothelioma. Silencing the receptor EphA2 gene is a novel approach for the containment of growth and migration of tumor in patients with malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17041885     DOI: 10.1002/cncr.22254

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

Review 1.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

2.  Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.

Authors:  Weibo Cai; Alireza Ebrahimnejad; Kai Chen; Qizhen Cao; Zi-Bo Li; David A Tice; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-03       Impact factor: 9.236

3.  EphA2 targeted intratumoral therapy for non-small cell lung cancer using albumin mesospheres.

Authors:  Hung-Yen Lee; Kamal A Mohammed; Fredric Kaye; Brij M Moudgil; Najmunnisa Nasreen
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

4.  EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

Authors:  Leonardo Faoro; Patrick A Singleton; Gustavo M Cervantes; Frances E Lennon; Nicholas W Choong; Rajani Kanteti; Benjamin D Ferguson; Aliya N Husain; Maria S Tretiakova; Nithya Ramnath; Everett E Vokes; Ravi Salgia
Journal:  J Biol Chem       Date:  2010-04-01       Impact factor: 5.157

5.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

6.  Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.

Authors:  J Jehle; I Staudacher; F Wiedmann; Pa Schweizer; R Becker; Ha Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 7.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

8.  Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

Authors:  Mayumi Kawabe; Maja Mandic; Jennifer L Taylor; Cecilia A Vasquez; Amy K Wesa; Leonard M Neckers; Walter J Storkus
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

9.  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.

Authors:  Dana M Brantley-Sieders; Guanglei Zhuang; Donna Hicks; Wei Bin Fang; Yoonha Hwang; Justin M M Cates; Karen Coffman; Dowdy Jackson; Elizabeth Bruckheimer; Rebecca S Muraoka-Cook; Jin Chen
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

10.  EphA2 overexpression promotes ovarian cancer growth.

Authors:  Chunhua Lu; Mian M K Shahzad; Hua Wang; Charles N Landen; Seung W Kim; Julie Allen; Alpa M Nick; Nicholas Jennings; Michael S Kinch; Menashe Bar-Eli; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2008-04-19       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.